Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025-2034.
Glucagon-like peptide 1 (GLP-1) is a member of the incretin hormone family, which plays a crucial role in enhancing insulin secretion in response to gut-derived signals. It is derived from a larger polypeptide molecule known as pre-proglucagon, which splits to form glucagon and other related hormones, including GLP-1. These hormones are termed "glucagon-like" due to their structural similarities and shared origin. While the pancreas and central nervous system secrete small amounts of GLP-1, its primary source is the L-cells lining the small intestine. To produce GLP-1 peptides and their analogues, advanced techniques such as solid-phase peptide synthesis (SPPS), solution-phase synthesis, or hybrid methods are used. These peptides can be manufactured at various scales, ranging from small research batches to large-scale commercial production, ensuring their availability for both scientific and therapeutic applications.
Liquid-phase peptide synthesis (LPPS) provides a scalable and environmentally sustainable approach for producing peptides, utilizing fewer chemicals and solvents compared to alternative techniques, thereby reducing waste and enhancing eco-friendliness. LPPS is particularly effective for synthesizing shorter peptides, delivering high purity and consistent results. Its solution-phase environment enables precise chemical reactions, facilitating efficient peptide bond formation that can lead to better yields and cost savings, which is especially important for producing custom peptide sequences.
The growing global prevalence of type 2 diabetes and obesity has significantly increased demand for GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide, which are known for their ability to manage blood glucose levels, support weight loss, and improve cardiovascular outcomes. This surge in demand is driving the need for large-scale peptide production, making contract development and manufacturing organizations (CDMOs) essential partners in this process. As peptides gain popularity for their high selectivity, potency, and favorable safety profiles, GLP-1 analogues have emerged as a key segment within the peptide therapeutics market, encouraging pharmaceutical companies to outsource their production to specialized CDMOs increasingly.
Competitive Landscape
Some of the Major Key Players in the GLP-1 Peptide Synthesis CDMO Market are:
- Bachem Holding AG
- CordenPharma
- PolyPeptide Group
- AmbioPharm
- CPC Scientific
- CSBio
- Creative Peptides
- Lonza
- Aurisco Pharmaceutical
- Hybio Pharmaceuticals
- Chinese Peptide Company
- Neuland Laboratories
- Divis Laboratories
- Supriya Lifescience
- Allsino Pharmaceutical Co. Ltd
Market Segmentation
The GLP-1 peptide synthesis CDMO market is segmented based on synthesis technology, service type, scale of operation, and end-user. Based on synthesis technology, the market is segmented into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), group-assisted purification peptide synthesis (GAP-PS), hybrid technology, and recombinant DNA technology. Based on the service type, the market is divided into analytical and process development, large-scale production, custom peptide synthesis, peptide modification, purification technology, formulation development, regulatory support, packaging and labeling, pre-formulation, and registration batches. Based on the scale of operation, the market is divided into clinical-scale manufacturing, commercial-scale manufacturing, and pilot-scale manufacturing. Based on the end-user, the market is divided into pharmaceutical companies, biotechnology companies, and research institutions.
The Solid-Phase Peptide Synthesis (SPPS) Segment is Expected to Have the Highest Growth Rate During the Forecast Period
Based on synthesis technology, the market is segmented into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), group-assisted purification peptide synthesis (GAP-PS), hybrid technology, and recombinant DNA technology. Among these, the solid-phase peptide synthesis (SPPS) segment is expected to have the highest growth rate during the forecast period. GLP-1 analogues, such as semaglutide and other long-chain, structurally complex peptides, are best synthesised via solid-phase peptide synthesis (SPPS). Compared to solution-phase techniques, it permits the gradual addition of amino acids, providing for more control and oversight. To improve the stability, bioactivity, and pharmacokinetics of GLP-1 analogues, SPPS also supports the addition of non-natural amino acids, PEGylation, lipidation, and other chemical modifications. Due to these qualities, SPPS is a crucial platform for the creation and manufacture of future-generation GLP-1 receptor agonists.
The Large-scale Production Segment Dominates the Market
Based on the service type, the market is divided into analytical and process development, large-scale production, custom peptide synthesis, peptide modification, purification technology, formulation development, regulatory support, packaging and labeling, pre-formulation, and registration batches. Among these, the large-scale production segment dominates the market. There is a demand for kilogram-scale, GMP-compliant peptide manufacturing, as many GLP-1 analogues have progressed from clinical development to full commercialization. Large-scale contract development and manufacturing organizations (CDMOs) are crucial for providing reliable, superior, and legally compliant manufacturing at industrial scales.
The cost-per-gram of peptide active pharmaceutical ingredients (APIs) is significantly decreased by economies of scale made possible by large-scale manufacture. Pharmaceutical businesses seeking dependable and efficient manufacturing partners find CDMOs with automated solid-phase peptide synthesis (SPPS) systems and optimized batch processes to be highly appealing, as they can offer competitive pricing and expedited turnaround times.
North America Has the Largest Market Share During the Forecast Period.
North America, particularly the US, is one of the largest markets for GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro. The demand for GLP-1 analogue manufacture is greatly influenced by the fact that the United States leads the world in pharmaceutical research and development, particularly in the fields of diabetes and obesity treatments. The region's contract development and manufacturing organizations (CDMOs) are favored partners for the clinical and commercial-scale manufacturing of GLP-1 peptides due to their sophisticated infrastructure and strict adherence to FDA standards. The market in North America is expected to increase due to its sophisticated manufacturing capabilities, robust pharmaceutical demand, and concentration of top-tier Contract Development and Manufacturing Organizations (CDMOs) that can support large-scale clinical and commercial peptide production.
Recent Developments:
- In Mar 2025, CordenPharma launched a greenfield peptide manufacturing plant in Basel, Switzerland, into operation. The company's 541 million investment is a component of a three-year peptide drive worth $1.08 billion. The strategy, which was unveiled in July 2024, intends to increase the production of glucagon-like peptide-1 (GLP-1) peptide in both the US and Europe. For both GLP-1 and non-GLP-1 peptide projects, the factory will include many peptide production manufacturing lines with solid phase peptide synthesis (SPPS) reactors larger than 5,000 L. The facility will comply with biologics license applications (BLAs) thanks to its cutting-edge automation and creative peptide manufacturing technology.
- In Mar 2024, Aurisco Pharmaceutical was delighted to report that its investment in cGMP peptide manufacturing capacity at its USFDA-inspected location in Yangzhou, China, is complete. The new advanced production and purification workshops offer a multi-metric ton capability to create Aurisco's generic GLP-1 peptides in addition to its existing fermentation and synthetic capabilities. With the confirmation of recombinant semaglutide on a commercial scale, the state-of-the-art facilities are scheduled to open in mid-2024.
- In Jul 2024, CordenPharma has committed to spending around €900 million over the next three years to expand its peptide technology platform, making it its greatest strategic investment to date. These transformative plans comprise two significant expansion initiatives that are taking place concurrently in the US and Europe. These initiatives include both new constructions and existing facilities that are designed and constructed per the strictest technical and quality standards for the manufacturing of short and long peptides set by the pharmaceutical industry, including requirements for Biologics License Applications (BLAs).
GLP-1 Peptide Synthesis CDMO Market Report Scope :
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 12.7 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Synthesis Technology, By Service Type, By Scale of Operation, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bachem Holding AG, CordenPharma, PolyPeptide Group, AmbioPharm, CPC Scientific, CSBio, Creative Peptides, Lonza, Aurisco Pharmaceutical, Hybio Pharmaceuticals, Chinese Peptide Company, Neuland Laboratories, Divis Laboratories, Supriya Lifescience, Allsino Pharmaceutical Co. Ltd |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
